-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 JR8sqcTOtWiFvATr8NkhSZUw5XkLFId7eHilpNPTUMJI9w/xml/CAtD+f+zZlanG
 gAt5epNgDZByVcJ2NXR7yg==

<SEC-DOCUMENT>0001157523-03-001042.txt : 20030415
<SEC-HEADER>0001157523-03-001042.hdr.sgml : 20030415
<ACCEPTANCE-DATETIME>20030415122216
ACCESSION NUMBER:		0001157523-03-001042
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20030408
ITEM INFORMATION:		Regulation FD Disclosure
FILED AS OF DATE:		20030415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OXIS INTERNATIONAL INC
		CENTRAL INDEX KEY:			0000109657
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				941620407
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-08092
		FILM NUMBER:		03649937

	BUSINESS ADDRESS:	
		STREET 1:		6040 N CUTTER CIRCLE STE 317
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97217
		BUSINESS PHONE:		5032833911

	MAIL ADDRESS:	
		STREET 1:		6040 N CUTTER CIRCLE STE 317
		CITY:			PORTLAND
		STATE:			OR
		ZIP:			97217

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DIAGNOSTIC DATA INC /DE/
		DATE OF NAME CHANGE:	19850312

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DDI PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a4375479.txt
<DESCRIPTION>OXIS INTERNATIONAL 8-K
<TEXT>
                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549
                                -----------------

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of
                       the Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported):

                                  April 8, 2003



                            OXIS INTERNATIONAL, INC.
             (Exact name of Registrant as specified in its charter)

          Delaware                      0-8092                   94-1620407
(State or other jurisdiction     (Commission File No.)          (IRS Employer
      of incorporation)                                      Identification No.)

            6040 N. Cutter Circle, Suite 317, Portland, Oregon 97217
               (Address of principal executive offices) (Zip Code)

       Registrant's telephone number, including area code: (503) 283-3911

                                 Not applicable
          (Former name or former address, if changed since last report)



<PAGE>




Item 9.  Regulation FD Disclosure

         This Current Report on Form 8-K is being furnished pursuant to Item 12,
"Results of Operations and Financial Condition," in accordance with interim
procedures promulgated by the Securities and Exchange Commission in Release No.
33-8176 that were issued March 28, 2003. See "Item 12. Results of Operations and
Financial Condition" below.

Item 12.  Results of Operations and Financial Condition.

         On April 8, 2003, OXIS International, Inc., issued a press release
announcing its sales results for the year ended December 31, 2002. The text of
the press release, which is attached as Exhibit 99.1, is incorporated by
reference in its entirety.



                                   SIGNATURES

         Pursuant to the requirements of the Securities and Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                                         OXIS International, Inc.
                                         (Registrant)



Date: April 11, 2003                     /s/ Sharon Ellis
                                         ---------------------------------------
                                           Sharon Ellis
                                           Chief Operating and Financial Officer


                                       2
<PAGE>



                                  EXHIBIT INDEX

Exhibit
Number   Description
- ------   -----------

99.1     Press Release issued by OXIS International, Inc., on April 8, 2003


                                       3
<PAGE>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>3
<FILENAME>a4375479ex99.txt
<DESCRIPTION>EXHIBIT 99.1 PRESS RELEASE
<TEXT>
                                                                  Exhibit 99.1

OXIS International Reports 2002 Results; Company Reduces Loss for the
Second Straight Year and Launches Animal Health Profiling in the
Cattle Industry

    PORTLAND, Ore.--(BUSINESS WIRE)--April 8, 2003--OXIS
International, Inc. (OTCBB:OXIS) (Nouveau Marche:OXIS) today announced
2002 year-end results, highlighting expanded distribution channels for
the Company's research products and commercial applications for the
profiling of cattle's susceptibility to disease.
    For the year ended December 31, 2002, the Company reported
revenues of $2,050,000, a decrease from $2,968,000 reported in 2001.
Cost of sales dropped from 82% in 2001 to 56% in 2002. Sales, general
and administrative costs also declined to $1,258,000 in 2002, down
from $2,287,000 in 2001.
    The net loss for the year was $822,000 or $0.08 per share, as
compared to $3,495,000, or $0.36 per share in 2001. The 2002 research
and development expenses were $463,000 compared to $762,000 in 2001.
    "During 2002, we continued with cost reduction and expansion of
new products and technologies into the market place and expanded the
distribution channels for our world class oxidative stress research
products," said Sharon Ellis, OXIS C.O.O. and C.F.O. "In addition to
geographic expansion, new applications for OXIS' technologies have
been developed and analyzed relative to the profiling of cattle's
susceptibility to disease."

    OXIS, headquartered in Portland, Oregon, focuses on developing
technologies and products to research, diagnose, treat and prevent
diseases associated with damage from free radical and reactive oxygen
species -- diseases of oxidative stress. The Company holds the rights
to three therapeutic classes of compounds in the area of oxidative
stress and, through its Health Products division, develops,
manufactures and markets products and technologies to diagnose and
treat diseases caused by oxidative stress.

    This press release contains forward-looking statements that
involve risks and uncertainties. Such uncertainties include the
Company's ability to fund, partner, out-license or otherwise support
certain of its assets; to establish relationships with third parties
at terms favorable to the Company; and other risks detailed in the
Company's filings with the SEC. These factors could cause actual
results to differ materially from those projected in the
forward-looking statements.

       CONDENSED UNAUDITED CONSOLIDATED STATEMENT OF OPERATIONS
                                             Year ended
                                             December 31,
                                     2002                     2001

Total revenues                   $ 2,050,000              $ 2,968,000

Cost and expenses:
     Cost of sales                 1,140,000                2,430,000
     Research & development          463,000                  762,000
     Sales, general & admin.       1,258,000                2,287,000
     Write down of inventory
        and equipment                     --                  942,000
                                 -------------------------------------
     Total costs & expenses        2,861,000                6,421,000
                                 -------------------------------------
Operating loss                      (811,000)              (3,453,000)
Litigation settlement                      --                 (57,000)
Interest income (expense), net       (11,000)                  15,000
                                 -------------------------------------
Net loss                         $  (822,000)             $(3,495,000)
                                 =====================================
Net loss per share               $      (.08)             $      (.36)
                                 =====================================


           UNAUDITED CONSOLIDATED BALANCE SHEET INFORMATION
                                                December 31,
                                            2002          2001
                   Current assets        $1,051,000   $   706,000
                   Total assets           1,985,000     1,721,000
                   Current liabilities      767,000     1,186,000
                   Total equity           1,218,000       553,000

    CONTACT: for OXIS International, Inc.
             Investor Relations:
             Investor Awareness, Inc.
             Tony Schor/Paul Arndt, 847/945-2222
             info@investorawareness.com
             or
             Media Relations:
             Obidicut LLC
             Will Anderson, 503/452-7621
             will@obidicut.net

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
